{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:36:57Z","timestamp":1785479817218,"version":"3.56.0"},"reference-count":33,"publisher":"American Psychiatric Association Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2005,1,1]]},"DOI":"10.1176\/appi.ajp.162.1.130","type":"journal-article","created":{"date-parts":[[2004,12,30]],"date-time":"2004-12-30T01:58:53Z","timestamp":1104371933000},"page":"130-136","source":"Crossref","is-referenced-by-count":191,"title":["Clozapine Augmented With Risperidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1176","volume":"162","author":[{"given":"Richard C.","family":"Josiassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kohegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Dadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wynn Wynn","family":"Paing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita A.","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R1621CACDJEHH","doi-asserted-by":"crossref","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (Clozaril Collaborative Study Group): Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789\u2013796","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"R1621CACHEAIH","doi-asserted-by":"crossref","unstructured":"Meltzer HY: Duration of a clozapine trial in neuroleptic resistant schizophrenia (letter). Arch Gen Psychiatry 1989; 46:672","DOI":"10.1001\/archpsyc.1989.01810070098017"},{"key":"R1621CACHBGCD","doi-asserted-by":"crossref","unstructured":"Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337:809\u2013815","DOI":"10.1056\/NEJM199709183371202"},{"key":"R1621CACCIHIC","doi-asserted-by":"crossref","unstructured":"Simpson GM, Josiassen RC, Stanilla JK, de Leon J, Nair C, Abraham G, Odom-White A, Turner RM: A double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry 1999; 156:1744\u20131750; correction, 2001; 158:834","DOI":"10.1176\/ajp.156.11.1744"},{"key":"R1621CACJBHCF","doi-asserted-by":"crossref","unstructured":"Wahlbeck K, Cheine M, Essali A, Adams C: Evidence of clozapine\u2019s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156:990\u2013999","DOI":"10.1176\/ajp.156.7.990"},{"key":"R1621CACCICIG","doi-asserted-by":"crossref","unstructured":"Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J: When symptoms persist: clozapine augmentation strategies. Schizophr Bull 2001; 27:615\u2013628","DOI":"10.1093\/oxfordjournals.schbul.a006901"},{"key":"R1621CACJAAGJ","unstructured":"Pollack S, Lieberman JA, Fleischhacker WW, Borenstein M, Safferman AZ, Hummer M, Kurz M: A comparison of European and American dosing regimens of schizophrenic patients on clozapine: efficacy and side effects. Psychopharmacol Bull 1995; 31:315\u2013320"},{"key":"R1621CACFDIBG","doi-asserted-by":"crossref","unstructured":"Freudenreich O, Goff DC: Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106:323\u2013330","DOI":"10.1034\/j.1600-0447.2002.01331.x"},{"key":"R1621CACHEFAF","doi-asserted-by":"crossref","unstructured":"Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A: Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 1997; 171:569\u2013573","DOI":"10.1192\/bjp.171.6.569"},{"key":"R1621CACHAGHH","doi-asserted-by":"crossref","unstructured":"Mowerman S, Siris SG: Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996; 8:193\u2013197","DOI":"10.3109\/10401239609147759"},{"key":"R1621CACFCGHH","doi-asserted-by":"crossref","unstructured":"Friedman J, Ault K, Powchik P: Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 1997; 42:522\u2013523","DOI":"10.1016\/S0006-3223(97)00227-8"},{"key":"R1621CACJBHGJ","doi-asserted-by":"crossref","unstructured":"Gupta S, Sonnenberg SJ, Frank B: Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998; 10:113\u2013115","DOI":"10.3109\/10401239809148944"},{"key":"R1621CACHBAAF","doi-asserted-by":"crossref","unstructured":"Adesanya A, Pantelis C: Adjunctive risperidone treatment in patients with \u201cclozapine-resistant schizophrenia.\u201d Aust NZ J Psychiatry 2000; 34:533\u2013534","DOI":"10.1080\/j.1440-1614.2000.0751j.x"},{"key":"atypb1","doi-asserted-by":"crossref","unstructured":"McCarthy RH, Terkelsen KG: Risperidone augmentation of clozapine. Pharmacology 1995; 28:61\u201363","DOI":"10.1055\/s-2007-979590"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"Morera AL, Barreiro P, Cano-Munoz JL: Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr Scand 1999; 99:305\u2013307","DOI":"10.1111\/j.1600-0447.1999.tb07230.x"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Raju Kumar R, Khanna S: Clozapine-risperidone combination in treatment-resistant schizophrenia (letter). Aust NZ J Psychiatry 2001; 35:543","DOI":"10.1046\/j.1440-1614.2001.0911d.x"},{"key":"R1621CACHGCAG","doi-asserted-by":"crossref","unstructured":"Raskin S, Katz G, Zislin Z, Knobler HY, Durst R: Clozapine and risperidone: combination\/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 2000; 101:334\u2013336","DOI":"10.1111\/j.1600-0447.2000.tb10935.x"},{"key":"R1621CACDIABJ","doi-asserted-by":"crossref","unstructured":"Chong SA, Remington G: Clozapine augmentation: safety and efficacy. Schizophr Bull 2000; 26:421\u2013440","DOI":"10.1093\/oxfordjournals.schbul.a033463"},{"key":"R1621CACFICEI","unstructured":"Henderson DC, Goff DC: Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996; 57:395\u2013397"},{"key":"R1621CACGEECJ","doi-asserted-by":"crossref","unstructured":"Taylor CG, Flynn SW, Altman S, Ehmann T, MacEwan GW, Honer WG: An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 2001; 48:155\u2013158","DOI":"10.1016\/S0920-9964(00)00104-3"},{"key":"R1621CACDFEGH","doi-asserted-by":"crossref","unstructured":"De Groot IW, Heck AH, van Harten PN: Addition of risperidone to clozapine therapy in chronically psychotic inpatients (letter). J Clin Psychiatry 2001; 62:129\u2013130","DOI":"10.4088\/JCP.v62n0210f"},{"key":"R1621CACCFBBJ","doi-asserted-by":"crossref","unstructured":"Wang PS, West JC, Tanielian T, Pincus HA: Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 2000; 26:451\u2013457","DOI":"10.1093\/oxfordjournals.schbul.a033465"},{"key":"R1621CACFEGCI","doi-asserted-by":"crossref","unstructured":"Weissman EM: Antipsychotic prescribing practices in the Veterans Healthcare Administration\u2014New York Metropolitan region. Schizophr Bull 2002; 28:31\u201342","DOI":"10.1093\/oxfordjournals.schbul.a006924"},{"key":"R1621CACGGAGC","doi-asserted-by":"crossref","unstructured":"Marder SR: Can clinical practice guide a research agenda? Schizophr Bull 2002; 28:127\u2013129","DOI":"10.1093\/oxfordjournals.schbul.a006915"},{"key":"atypb4","doi-asserted-by":"crossref","unstructured":"Miller AL, Craig CS: Combination antipsychotics: pros, cons, and questions. Schizophr Bull 2002; 28:105\u2013109","DOI":"10.1093\/oxfordjournals.schbul.a006912"},{"key":"atypb5","doi-asserted-by":"crossref","unstructured":"Stahl SM: Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J Clin Psychiatry 1999; 60:425\u2013426","DOI":"10.4088\/JCP.v60n0701"},{"key":"R1621CACEEGCE","doi-asserted-by":"crossref","unstructured":"Stahl SM: Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry 2002; 63:93\u201394","DOI":"10.4088\/JCP.v63n0201"},{"key":"R1621CACIEHDD","unstructured":"Woerner MG, Mennuzza S, Kane JM: Anchoring the BPRS-A: an aid to improved reliability. Psychopharmacol Bull 1988; 24:112\u2013117"},{"key":"R1621CACBJFJH","doi-asserted-by":"crossref","unstructured":"Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11\u201319","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"R1621CACFCFHD","doi-asserted-by":"crossref","unstructured":"Stern RG, Schmeidler J, Davidson M: Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry 1997; 42:138\u2013143","DOI":"10.1016\/S0006-3223(96)00295-8"},{"key":"R1621CACEEJFE","doi-asserted-by":"crossref","unstructured":"Godleski LS, Sernyak MJ: Agranulocytosis after addition of risperidone to clozapine treatment (letter). Am J Psychiatry 1996; 153:735\u2013736","DOI":"10.1176\/ajp.153.5.735b"},{"key":"R1621CACIIAEH","doi-asserted-by":"crossref","unstructured":"Tyson SC, Devane CL, Risch SC: Pharmacokinetic interaction between risperidone and clozapine (letter). Am J Psychiatry 1995; 152:1401\u20131402","DOI":"10.1176\/ajp.152.9.1401b"},{"key":"R1621CACGHGAJ","doi-asserted-by":"crossref","unstructured":"Henderson DC, Goff DC, Connolly CE, Borba CP, Hayden D: Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 2001; 62:605\u2013608","DOI":"10.4088\/JCP.v62n0805"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.162.1.130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T02:05:18Z","timestamp":1722391518000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.162.1.130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"alternative-id":["10.1176\/appi.ajp.162.1.130"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.162.1.130","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}